CME Group (CME) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
16 Apr, 2026Executive summary
Annual Meeting of Shareholders scheduled for May 14, 2026, with proxy materials filed and available for review.
Shareholders are encouraged to read all proxy materials before voting, as they contain important information about the meeting and company matters.
Several candidates for Board of Directors positions present their qualifications, experience, and vision for the company’s future.
Voting matters and shareholder proposals
Shareholders are urged to vote using their unique 16-digit control numbers, with instructions provided for obtaining these if lost.
Voting can be conducted online or by phone, with Broadridge serving as Inspector of Election.
Board of directors and corporate governance
Multiple candidates seek re-election or election to the Board, emphasizing diverse trading backgrounds and decades of industry experience.
Candidates highlight committee roles, including risk, finance, audit, and compensation, and stress advocacy for market participants.
Board members stress the importance of adapting to technological change and maintaining strong governance.
Candidates note their participation in various CME Group and industry committees, reflecting broad governance involvement.
Latest events from CME Group
- Shareholders will vote on director elections, auditor ratification, and key governance amendments.CME
Proxy filing23 Mar 2026 - Shareholders to vote on major governance reforms, executive pay, and director elections.CME
Proxy filing23 Mar 2026 - Proposal to eliminate Class B director election rights, with payments to affected shareholders.CME
Proxy Filing12 Mar 2026 - Shareholders to vote on eliminating Class B director election rights amid record financial performance.CME
Proxy Filing12 Mar 2026 - Global growth, product innovation, and high margins drive record performance and shareholder returns.CME
47th Annual Raymond James Institutional Investor Conference3 Mar 2026 - Record 2025 growth fueled by innovation, global reach, and strong capital efficiencies.CME
Investor presentation3 Mar 2026 - Record revenue, earnings, and trading volumes in 2025, with strong capital returns.CME
Q4 20254 Feb 2026 - Record financials, all proposals approved, and strong outlook amid competition and litigation.CME
AGM 20253 Feb 2026 - Record Q2 revenue, net income, and trading volumes, with growth in every asset class and strong margins.CME
Q2 20243 Feb 2026